<DOC>
	<DOCNO>NCT00574626</DOCNO>
	<brief_summary>The purpose study evaluate difference relapse rate long term event free survival patient intermediate grade immunoblastic non-Hodgkin 's lymphoma ( NHL ) whose marrow obviously involved NHL randomize receive either autologous bone marrow ( ABMT ) peripheral stem cell transplant ( PSCT ) . All patient intermediate grade NHL histologic negative bone marrow would otherwise meet eligibility criterion high-dose therapy ABMT eligible study . Patients eligible randomize either PSCT ABMT time enrollment transplant program .</brief_summary>
	<brief_title>Randomized Trial Comparing Autologous PBSCT BMT Pts Receiving High-Dose Chemo &amp; Transplant Recurrent NHL</brief_title>
	<detailed_description>These patient would enrol high-dose protocol use carmustine , etoposide , cytarabine , cytoxan ( BEAC ) autologous hematopoietic rescue . The patient stratify accord good poor prognosis category relapse vs. first partial response category . The patient bone marrow peripheral stem cell collect accord standard protocol . A standardized hematopoietic growth factor use mobilization post-transplant . The patient ' PSC BM product assay via invitro-culture technique occult tumor , molecular biologic assay . The patient ' outcome transplantation evaluate response transplantation , relapse rate event free survival measure end point .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Age 1665 Intermediate grade nonHodgkin 's lymphoma ( International Working Formulation Follicular large cell , Diffuse Small Cleaved , Diffuse Mixed , Diffuse Large Cell , Immunoblastic ) histologic negative bone marrow would otherwise meet eligibility criterion highdose therapy ABMT . These criterion specific highdose therapy protocol ( i.e . Karnofsky performance status &gt; 70 , adequate organ function , HIV Hepatitis B negative , etc. ) . These patient would enrol highdose protocol use carmustine , etoposide , cytarabine , cytoxan ( BEAC ) autologous hematopoietic rescue . Patients bone marrow histologically involved tumor bone marrow abnormality make bone marrow harvest possible . Patients whose tumor rapidly grow may preclude extra time involve PSC collection process . Patients otherwise meet highdose therapy transplantation entry criterion .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>NHL</keyword>
	<keyword>Non Hodgkins Lymphoma</keyword>
	<keyword>BMT</keyword>
	<keyword>Bone Marrow Transplant</keyword>
	<keyword>PBSCT</keyword>
	<keyword>Peripheral Blood Stem Cell Transplant</keyword>
	<keyword>PSCT</keyword>
</DOC>